Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Solange Peters

Showing results (91-100 of 362) with videos related to

Pageof 37
Sort By:
Nature Reviews. Clinical Oncology|August 15, 2025
Treatment of NSCLC after chemoimmunotherapy - are we making headway?Martin Reck, Nikolaj Frost, Solange Peters, et al.
Frontiers in Oncology|July 5, 2021
Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two CasesLouis Gros, Petr Szturz, Antonella Diciolla, et al.
Journal for Immunotherapy of Cancer|June 28, 2023
Cytokine storm complicated by cardiogenic shock induced by anti-HER2 therapiesRita Godinho, Alessandra Noto, Craig Fenwick, et al.
Revue Medicale Suisse|May 18, 2022
[Targeted therapies and non-small cell carcinomas : novelties]Roberta Stauber, Louis Gro S, Tu Nguyen-Ngoc, et al.
Revue Medicale Suisse|May 16, 2019
[The new management options for lung cancer in the immunotherapy era]Heyfa Meganem, Roxana-Maria Socianu, Hasna Bouchaab, et al.
Melanoma Research|September 5, 2014
Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patientSolange Peters, Hasna Bouchaab, Stefan Zimmerman, et al.
Cancer Cell|May 27, 2020
The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with CancerSamuel M Rubinstein, John A Steinharter, Jeremy Warner, et al.
Lung Cancer (Amsterdam, Netherlands)|February 6, 2013
A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable?Nadine Demierre, Vincent Zoete, Olivier Michielin, et al.
Cancer Treatment Reviews|February 8, 2022
Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysisAaron C Tan, Sze Huey Tan, Siqin Zhou, et al.
Lung Cancer (Amsterdam, Netherlands)|December 23, 2023
Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT)Cesare Gridelli, Solange Peters, Tony Mok, et al.
Pageof 37

Showing results (91-100 of 362) with videos related to

Sort By:
Pageof 37
Nature Reviews. Clinical Oncology|August 15, 2025
Treatment of NSCLC after chemoimmunotherapy - are we making headway?Martin Reck, Nikolaj Frost, Solange Peters, et al.
Frontiers in Oncology|July 5, 2021
Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two CasesLouis Gros, Petr Szturz, Antonella Diciolla, et al.
Journal for Immunotherapy of Cancer|June 28, 2023
Cytokine storm complicated by cardiogenic shock induced by anti-HER2 therapiesRita Godinho, Alessandra Noto, Craig Fenwick, et al.
Revue Medicale Suisse|May 18, 2022
[Targeted therapies and non-small cell carcinomas : novelties]Roberta Stauber, Louis Gro S, Tu Nguyen-Ngoc, et al.
Revue Medicale Suisse|May 16, 2019
[The new management options for lung cancer in the immunotherapy era]Heyfa Meganem, Roxana-Maria Socianu, Hasna Bouchaab, et al.
Melanoma Research|September 5, 2014
Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patientSolange Peters, Hasna Bouchaab, Stefan Zimmerman, et al.
Cancer Cell|May 27, 2020
The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with CancerSamuel M Rubinstein, John A Steinharter, Jeremy Warner, et al.
Lung Cancer (Amsterdam, Netherlands)|February 6, 2013
A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable?Nadine Demierre, Vincent Zoete, Olivier Michielin, et al.
Cancer Treatment Reviews|February 8, 2022
Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysisAaron C Tan, Sze Huey Tan, Siqin Zhou, et al.
Lung Cancer (Amsterdam, Netherlands)|December 23, 2023
Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT)Cesare Gridelli, Solange Peters, Tony Mok, et al.
Pageof 37